BioMedNewsBreaks Archive - Page 92 of 246

ThursdayNov 09, 2023 10:31 am

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) CMO Featured in Latest Bell2Bell Podcast Release

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is in the spotlight during a recent episode of The Bell2Bell podcast. During the podcast, PaxMedica chief medical officer David Hough and host Stuart Smith discuss key company achievements, including the company’s recent meeting with the U.S. Food and Drug Administration (“FDA”). Highlights mentioned during the podcast include the discussion with the FDA of data gathered from the company’s PAX-HAT 301 study and other comprehensive nonclinical programs. Hough explained that the study provided positive evidence regarding the company’s treatment for African Sleeping Sickness treatment; he also noted…

WednesdayNov 08, 2023 3:26 pm

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB), GEDi Cube Combine to Transform Medicine Through AI and Biotherapeutics

Renovaro BioSciences (NASDAQ: RENB), a preclinical biotechnology company involved in the development of enhanced gene, cell and immunotherapy platforms that modulate immune responses against cancers and infectious disease, and GEDi Cube International Ltd., an AI medical technology company, recently entered a definitive agreement to combine in a stock-for-stock acquisition. “The combined company will feature two main divisions: the AI division and the immunotherapy division, according to an Oct. 2 message to shareholders from Renovaro CEO Mark Dybul, M.D. With a mission to transform medicine, the two divisions will leverage the strengths of each other yet maintain flexible independent operations. Bringing…

WednesdayNov 08, 2023 11:36 am

BioMedNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) to Serve as Official Title Sponsor of ‘A Special Private Evening with Luke Bryan’

Safety Shot (NASDAQ: SHOT) today announced that it is the official title sponsor of Save Our Musicians event, “A Special Private Evening with Luke Bryan.” At the charity concert event taking place on Nov. 18, 2023, in Jupiter, Florida, country superstar and American Idol judge Luke Bryan will be performing to raise money for the arts in public schools. The concert follows a similar successful Save Our Musicians fundraiser featuring Gwen Stefani, which also raised funds for arts education and garnered over 3 million views on social media. The Safety Shot brand and logo will be prominent on the event’s…

TuesdayNov 07, 2023 12:31 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Phase 2 Study Results Published in Peer-Reviewed Journal

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is reporting that its phase 2 study research exploring the potential of low-dose suramin intravenous infusions as an autism spectrum disorder (“ASD”) treatment has been published. According to the announcement, the findings from the study were published in the “Annals of General Psychiatry.” The company noted that the research had been led by PaxMedica CMO Dr. David Hough, who worked with a team of renowned ASD specialists. The research was based on a comprehensive, 14-week randomized, double-blind, placebo-controlled study with 52 participants diagnosed with moderate to severe…

TuesdayNov 07, 2023 10:29 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Q3 2023 Financial Results, Operating Highlights

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., today released its third quarter 2023 financial results and provided recent operating highlights for its ALS clinical program. Among the highlights, the company reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8(R) in the RESCUE ALS open-label extension trial. “We are pleased to be approaching a meaningful regulatory discussion with the U.S. Food and Drug Administration (‘FDA’) later in the fourth quarter to elucidate key next steps in our ALS regulatory submission of CNM-Au8,”…

TuesdayNov 07, 2023 10:20 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receive $900K IIA Grant for New CDMO Business Unit

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, has been named the recipient of a grant from the Israel Innovation Authority (“IIA”). According to the announcement, the IIA, which is publicly funded and part of Israel’s Ministry of Economy, approved a nondilutive grant covering 66% of the costs of an ILS 3,536,939 project aimed at ramping up Scinai’s new CDMO business unit; the approximate value of the grant is $900,000. The announcement noted that the grant is not subject to…

MondayNov 06, 2023 1:30 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Status Report on NASDAQ Compliance

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, has received a letter from the NASDAQ Stock Market. Dated Nov. 1, 2023, the letter is regarding SCNI’s noncompliance with the market’s requirement to maintain a minimum bid price of $1 per share. According to the report, Scinai has an initial period of 180 calendar days to regain compliance; that period ends on April 29, 2024. The company will be notified if compliance has been achieved any time during that period. Scinai will…

FridayNov 03, 2023 12:38 pm

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Plans to Release Q3 2023 Financial Report, Host Corporate Update Call

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, has announced plans to report its financial results for Q3 2023. The company will release the results on Nov. 10, 2023, before the market opens. In addition, the company announced plans to host a conference call and webcast that same day. During the call, key company leaders will discuss the Q3 financial report as well as provide an update on its clinical programs and corporate activities; the call will also include time for a Q&A. To access the call, individuals should dial 1-877-407-0789 (domestic)…

ThursdayNov 02, 2023 11:57 am

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD), Bourne Partners to Collaborate in Evaluating Future Monetization of Potential PRV

PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, is working with leading financial services firm Bourne Partners. Bourne Partners specializes in the pharma, pharma services and consumer health spaces. According to the announcement, the collaboration is an important step in PaxMedica's strategy to explore potential monetization of a Priority Review Voucher prior to filing the NDA for PAX-101 for the treatment of African Sleeping Sickness. Although PaxMedica has not yet been granted a PRV and there is no guarantee that one will be awarded, the company believes PAX-101 qualifies for the PRV program because African Sleeping…

ThursdayNov 02, 2023 10:39 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present Phase 2 Study Results for INM-755 at 12th Annual WCI

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be presenting an oral presentation at the 12th World Congress on Itch (“WCI”); the event is scheduled for Nov. 5–7, 2023, in Miami. According to the announcement, the oral presentation is based on an abstract describing the phase 2 clinical study of investigational drug INM-755 cannabinol cream for the treatment of symptoms in patients with rare genetic skin disease called epidermolysis bullosa ("EB"). InMed Pharmaceuticals senior vice president of Clinical and Regulatory Affairs Alexandra Mancini will be presenting. The…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) CMO Featured in Latest Bell2Bell Podcast Release

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB), GEDi Cube Combine to Transform Medicine Through AI and Biotherapeutics

BioMedNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) to Serve as Official Title Sponsor of ‘A Special Private Evening with Luke Bryan’

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Phase 2 Study Results Published in Peer-Reviewed Journal

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Q3 2023 Financial Results, Operating Highlights

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receive $900K IIA Grant for New CDMO Business Unit

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Status Report on NASDAQ Compliance

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Plans to Release Q3 2023 Financial Report, Host Corporate Update Call

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD), Bourne Partners to Collaborate in Evaluating Future Monetization of Potential PRV

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present Phase 2 Study Results for INM-755 at 12th Annual WCI

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search